Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Somapacitan (Primary)
- Indications Somatotropin deficiency
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 07 Nov 2017 Planned End Date changed from 31 Mar 2018 to 30 Apr 2018.
- 07 Nov 2017 Status changed from not yet recruiting to recruiting.
- 13 Jul 2017 New trial record